ClinicalTrials.gg

Program

MEDI0618

A development code.

In AbbVie's pipeline, PAR-2. Its studies are mostly in Chronic Pain · Migraine Disorders, led by 2 companies.

Furthest: phase 2, since Nov 25, 20193 company-led studies, 1 open or runningNext primary completion: Feb 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca20 open or runningphase 1since Nov 25, 2019Nov 25, 2019none ahead
AbbVie11 open or runningphase 2since Sep 16, 2024Sep 16, 2024Feb 2027phase 2 · NCT06602479
  • Named in AbbVie’s own pipeline as ABBV-2002, phase 2, as of Jul 30, 2026 (source).

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 25, 2019First study: phase 1 study in Chronic PainNew to AstraZenecaAstraZeneca · NCT04198558 · 64 enrolled · Germany
  2. Dec 12, 2022Phase 1 study in Chronic PainAstraZeneca · NCT05714254 · 36 enrolled · Germany
  3. Sep 16, 2024AbbVie's first study: phase 2 study in Migraine DisordersNew to AbbVieAbbVie · NCT06602479 · 309 enrolled · United States, Czechia, Denmark and more

Ahead

  1. Feb 2027Primary completion: phase 2 study in Migraine DisordersAbbVie · NCT06602479

TargetBeta

“PAR-2”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06602479Migraine Disorders · United States, Czechia, Denmark and more2Active, not recruitingAbbVieFeb 2027309
NCT05714254Chronic Pain · Germany1CompletedAstraZenecaDec 12, 202336
NCT04198558Chronic Pain · Germany1CompletedAstraZenecaFeb 23, 202264

How it is read

Names in the registry

  • “MEDI0618”, 3 entries

Codes read as this program: MEDI0618.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.